Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce

  • Partnership aims to develop drugs for neurodegenerative diseases

  • Denali will draw on Lonza’s expertise in developing and manufacturing complex biologic molecules 

BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.

A major hurdle for treating neurodegenerative diseases is the inability of most biologics to cross the tightly controlled blood-brain barrier (BBB). Denali is engineering its biologic product candidates to overcome this fundamental obstacle. Manufacturing these sophisticated therapies requires a tailor-made approach, together with expertise and agility in cell line, process and formulation development.

Read Full Article Here:

Recent Posts

See All

Contact Us | Disclaimer Privacy Policy | Partners Innovation

© Copyright Partners Innovation Fund